Abstract
Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R 2 =0.27) than the IWPC pharmacogenomics (R 2 =0.15) or clinical (R 2 =0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring ≥60 mg per week (β=-2.04, P=0.02).
Original language | English (US) |
---|---|
Pages (from-to) | 223-228 |
Number of pages | 6 |
Journal | Pharmacogenomics Journal |
Volume | 14 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2014 |
Funding
This work was funded in part by the National Heart Lung and Blood Institute (K23 HL089808-01A2 to MAP), a grant from the American Heart Association Midwest Affiliate Grant-In-Aid (10GRNT3750024 to LHC) and by a grant from the National Collaborative on Aging (TJO).
Keywords
- African Americans
- CYP2C9
- VKORC1
- algorithm
- polymorphisms
- warfarin
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology